1 results match your criteria: "Department of Medical Oncology Liaoning Cancer Hospital and Institute Shenyang China.[Affiliation]"
Article Synopsis
- This study investigated the effectiveness and safety of anlotinib as a treatment for small cell lung cancer (SCLC) patients who also had brain metastases (BM), showing a poor prognosis.
- An analysis of the ALTER1202 trial revealed that patients treated with anlotinib had significantly improved progression-free survival (3.8 months) and overall survival (6.1 months) compared to those receiving a placebo.
- Anlotinib showed potential in delaying CNS progression and had a manageable side effect profile, with common serious adverse effects including increased lipase levels and hypertension.